7 results about "V600E" patented technology

The invention provides application of an intracellular lactic acid level increasing agent in preparation of a drug for enhancing sensitivity of BRAF V600E mutant tumors to a BRAF inhibitor or in preparation of a drug for treating BRAF V600E mutant tumors resistant to the BRAF inhibitor. According to the invention, the intracellular lactic acid concentration is improved by using an intracellular lactic acid level improver, SUMOylation of BRAFV600E protein is promoted, and the BRAFV600E protein is locked in an open drug sensitive conformation; in-vivo and in-vitro experiments prove that the combination of the MCT4 inhibitor and the BRAF inhibitor (such as vimofenib) has a remarkable synergistic anti-tumor effect, drug resistance can be effectively relieved, and a new treatment strategy is provided for refractory colorectal cancer and the like.

The application belongs to the technical field of immunochemistry, and particularly relates to an anti-BRAF-V600E recombinant rabbit monoclonal antibody and application thereof, which comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO: 4, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO: 5. The application also relates to a nucleotide sequence, a recombinant plasmid or an expression vector, a preparation method and application of the anti-BRAF-V600E recombinant rabbit monoclonal antibody in a BRAF-V600E protein detection method or device. The BRAF-V600E recombinant rabbit monoclonal antibody of the 135K5D1 clone of the application is good in specificity, strong in positive signal and the like, and is easier to score in IHC staining, and is more accurate in detection and distinction of cancer.

The invention discloses a noninvasive exosome mRNA BRAF V600E mutation Tag-PCR (Tag-Polymerase Chain Reaction) detection method, which comprises the following steps: separating an exosome sample from a body fluid; the method comprises the following steps: by taking mRNA as a template, adding an exogenous reference gene and a primer pair for detecting the exogenous reference gene, and meanwhile, carrying out a first round of PCR amplification reaction by using a Tag-ARMS primer pair for specifically enriching exosome mRNA BRAF gene V600E mutation so as to form a PCR product; a PCR product is used as a template, a system without UNG enzyme is used for amplification, a primer pair for detecting a reference gene is added, a Tag primer pair for specifically enriching and detecting V600E mutation of the human exosome mRNA BRAF gene and a probe sequence are used at the same time, and then a second round of PCR amplification reaction is carried out; and judging the mutation state of the V600E site of the BRAF gene of the mRNA of the exosome sample.

The application discloses a combination of a MEK inhibitor and a PLCbeta / PKC signal path inhibitor and application of the combination in treating BRAF(V600E) mutant tumors, and belongs to the field of biological medicines. The PLCbeta / PKC signal path inhibitor is combined with the MEK inhibitor, drug resistance can be reversed, stronger anti-BRAF(V600E) mutant tumor activity is exhibited, the growth of tumors can be more effectively inhibited, and the defects of poor treatment effect or large toxic side effects of single drug treatment are overcome. The application has a good application prospect.

The invention belongs to the technical field of immunochemistry, and particularly relates to an anti-BRAF-V600E recombinant rabbit monoclonal antibody and application thereof.The anti-BRAF-V600E recombinant rabbit monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO: 4; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 5. The invention also relates to a nucleotide sequence for coding the anti-BRAF-V600E recombinant rabbit monoclonal antibody, a recombinant plasmid or an expression vector, a preparation method of the anti-BRAF-V600E recombinant rabbit monoclonal antibody, application of the anti-BRAF-V600E recombinant rabbit monoclonal antibody in a BRAF-V600E protein detection method or device, and the like. The BRAF-V600E recombinant rabbit monoclonal antibody cloned from 135K5D1 has the characteristics of good specificity, strong positive signal and the like, so that scoring is easier in IHC staining, and cancer detection and distinguishing are more accurate.

The application discloses a primer probe composition for detecting a BRAF V600 gene mutation, a kit and application thereof. The application discloses a primer probe composition for detecting a BRAF V600 gene mutation, which comprises forward primers V600M-F and V600E-F shown in SEQ ID NO. 1 and SEQ ID NO. 2, a reverse primer V600R shown in SEQ ID NO. 3 and a detection probe V600P shown in SEQ ID NO. 4. Further disclosed are a kit containing the primer probe composition and application thereof. The primer probe composition is used for detecting a sample to be detected, has high sensitivity and specificity, can detect multiple BRAF V600 gene mutations, and can directly determine whether there is a mutation according to an amplification curve, without the need of calculating ΔCt, and is simple and direct.

This invention discloses the application of the small molecule drug PLX4032 in the preparation of a drug for the treatment of cerebral arteriovenous malformation. The small molecule drug PLX4032 of this invention can inhibit Braf... V600E Overactivation of the mutant protein Braf-MEK1 signaling pathway, thereby reducing Braf V600E The mutant protein's kinase activity, thereby preventing Braf from occurring in arteriovenous malformations of the brain. V600E The expression of mutant proteins can directly target diseased cells, resulting in good therapeutic effects.